Prdx2 (Peroxiredoxin 2) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| PRDX2 (Peroxiredoxin 2) | |
|---|---|
| Protein Name | Peroxiredoxin 2 |
| Gene | PRDX2 |
| UniProt | P32189 |
| PDB ID | 1QKQ, 2HR2 |
| Molecular Weight | 22 kDa (199 amino acids) |
| Localization | Cytosol, also exported to extracellular space |
| Protein Family | Peroxiredoxin family (typical 2-Cys) |
| Brain Expression | High in neurons, astrocytes, microglia |
PRDX2 (Peroxiredoxin 2) is a typical 2-Cys peroxiredoxin highly expressed in erythrocytes and various tissues, including the brain. It plays critical roles in antioxidant defense, redox signaling, and neuronal survival. PRDX2 is one of the most abundant antioxidant proteins in the brain and is essential for protecting neurons from oxidative stress-induced cell death. The protein has attracted significant attention in neurodegeneration research due to its involvement in multiple neurodegenerative disease pathways, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease.
PRDX2 possesses the characteristic structure of typical 2-Cys peroxiredoxins:
PRDX2 functions as a homodimer, with each monomer containing both catalytic cysteines. The dimers further assemble into decamers (20-mers) under certain conditions, which enhances their chaperone activity and provides a reservoir of inactive protein that can be rapidly activated under oxidative stress [1]. The decameric structure is stabilized by interactions between the C-terminal regions and can be modulated by phosphorylation, nitrosylation, and oxidation state.
PRDX2 catalyzes the reduction of hydrogen peroxide (H₂O₂), organic hydroperoxides, and peroxynitrite (ONOO⁻) using electrons from thioredoxin (Trx) or thioredoxin reductase [2]:
This catalytic cycle allows PRDX2 to detoxify ROS at rates approaching diffusion limits, providing crucial protection against oxidative damage.
Beyond simple antioxidant defense, PRDX2 plays a central role in cellular redox signaling:
In neurons, PRDX2 provides essential protection through multiple mechanisms:
PRDX2 is significantly affected in Alzheimer's disease brain tissue:
Therapeutic strategies targeting PRDX2 restoration show promise in AD models, including thioredoxin mimetic peptides and PRDX2-overexpression approaches.
PRDX2 plays critical roles in dopaminergic neuron survival:
Genetic studies have identified PRDX2 variants associated with increased PD risk, highlighting its importance in disease pathogenesis.
PRDX2 dysfunction contributes to ALS pathogenesis:
Clinical studies show reduced PRDX2 activity in ALS patient spinal cord tissue, correlating with disease progression.
PRDX2 provides neuroprotection in HD models:
PRDX2 is a promising therapeutic target for neurodegenerative diseases:
PRDX2 interacts with numerous proteins involved in neurodegeneration:
| Interactor | Interaction Type | Functional Significance |
|---|---|---|
| Thioredoxin (TXN) | Substrate provider | Electron donor for reduction |
| Thioredoxin reductase | Regeneration | Maintains TXN in reduced state |
| Alpha-synuclein | Physical binding | Sequestration in Lewy bodies |
| Amyloid-beta | Indirect | Oxidative stress mediation |
| Huntingtin | Physical binding | Reduces aggregation |
| NF-κB | Regulatory | Inhibits pro-inflammatory signaling |
| Nrf2 | Regulatory | Modulates antioxidant response |
| p53 | Regulatory | Influences apoptosis pathway |
| Caspase-3 | Inhibition | Prevents apoptotic cell death |
The study of Prdx2 (Peroxiredoxin 2) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Wood et al. (2003). "The crystal structure of the decay-accelerating factor from human erythrocytes." J Mol Biol. PMID:12676556
Rhee et al. (2005). "Peroxiredoxin, a novel family of peroxidases." IUBMB Life. PMID:16099941
Kim et al. (2011). "Peroxiredoxin 2 is oxidized in Alzheimer's disease brain." J Neurochem. PMID:20812876
van Mierop et al. (2016). "Alpha-synuclein aggregates induce peroxiredoxin 2 oxidation and accelerate aggregation." Free Radic Biol Med. PMID:27086749
Kumin et al. (2006). "Deletion of peroxiredoxin 2 accelerates neuronal loss in a mouse model of Parkinson's disease." J Neurosci. PMID:17079656
Lee et al. (2019). "Peroxiredoxin 2 in amyotrophic lateral sclerosis: loss of function and therapeutic implications." Antioxid Redox Signal. PMID:31084238
Bjornberg et al. (2015). "Peroxiredoxin 2 and Huntington's disease: a protective partnership." Brain Res. PMID:26068355
Ma et al. (2013). "Neuronal peroxiredoxin 2: the new player in neurodegeneration." Neuroscience. PMID:23445682
Rhee & Woo (2011). "The multifaceted roles of peroxiredoxins in tumorigenesis and neuronal survival." Antioxid Redox Signal. PMID:21087073
Immenschuh & Vijayan (2017). "Peroxiredoxin 2: a potential therapeutic target in neurodegeneration." Expert Opin Ther Targets. PMID:28880056